Larimar Therapeutics (LRMR) Cash & Equivalents (2013 - 2026)
Larimar Therapeutics' Cash & Equivalents was $92.69 million in Q2 2026, up 350.2% from $20.59 million a year earlier.
Powered by 
Analysis
Larimar Therapeutics (LRMR) Cash & Equivalents (2013 - 2026) Analysis & Trends
At the end of FY2025, Cash & Equivalents at Larimar Therapeutics came in at $85.41 million, up 157.1% from FY2024.
- Cash & Equivalents shows a five-year compound annual growth rate of 4.6% (FY2020 to FY2025).
- In earlier years, Cash & Equivalents was $33.22 million in FY2024 (+24.2%), $26.75 million in FY2023 (-0.3%), $26.83 million in FY2022 (-61.7%) and $70.1 million in FY2021 (+2.9%).
- The Q2 2026 figure marks the highest quarterly Cash & Equivalents since Q1 2024.
- Compared with a year earlier, Cash & Equivalents was higher in four of the last seven quarters, with growth averaging 80.3%.
- The best year-over-year quarter for Cash & Equivalents over five years was Q2 2023 (growth of 377.9%); the worst was Q1 2025 (a decline of 80.8%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 20.42 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 6.57 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 6.85 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 7.62 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 4.89 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 13.99 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 3.18 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 976.00 Mn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 6.14 Bn |
| 10 | Larimar Therapeutics | 331.39 Mn | -275.69 Mn | - | 92.69 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 92.69 Mn |
| Dec 31, 2025 | 85.41 Mn |
| Sep 30, 2025 | 90.14 Mn |
| Jun 30, 2025 | 20.59 Mn |
| Mar 31, 2025 | 21.13 Mn |
| Dec 31, 2024 | 33.22 Mn |
| Sep 30, 2024 | 35.07 Mn |
| Jun 30, 2024 | 32.31 Mn |
| Mar 31, 2024 | 110.13 Mn |
| Dec 31, 2023 | 26.75 Mn |
| Sep 30, 2023 | 38.72 Mn |
| Jun 30, 2023 | 94.32 Mn |
| Mar 31, 2023 | 111.52 Mn |
| Dec 31, 2022 | 26.83 Mn |
| Sep 30, 2022 | 86.05 Mn |
| Jun 30, 2022 | 19.74 Mn |
| Mar 31, 2022 | 62.56 Mn |
| Dec 31, 2021 | 70.10 Mn |
| Sep 30, 2021 | 71.53 Mn |
| Jun 30, 2021 | 70.63 Mn |
API Access
Larimar Therapeutics Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=LRMR&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "LRMR", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=LRMR&period=max&api_key=YOUR_API_KEY");
const data = await res.json();